Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer.

Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA Jr, Cote GJ, Sherman SI.

J Clin Endocrinol Metab. 2016 Nov;101(11):4461-4467. Epub 2016 Aug 30.

2.

Response.

Overholt BF, Wheeler DJ, Jordan T, Fritsche HA.

Gastrointest Endosc. 2016 Oct;84(4):754. doi: 10.1016/j.gie.2016.07.019. No abstract available.

PMID:
27633369
3.

Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System.

Albitar M, Ma W, Lund L, Albitar F, Diep K, Fritsche HA, Shore N.

J Cancer. 2016 Feb 2;7(3):297-303. doi: 10.7150/jca.12771. eCollection 2016.

4.

CA11-19: a tumor marker for the detection of colorectal cancer.

Overholt BF, Wheeler DJ, Jordan T, Fritsche HA.

Gastrointest Endosc. 2016 Mar;83(3):545-51. doi: 10.1016/j.gie.2015.06.041. Epub 2015 Aug 28.

PMID:
26318832
5.

Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.

Ma W, Diep K, Fritsche HA, Shore N, Albitar M.

Genet Test Mol Biomarkers. 2014 Mar;18(3):156-63. doi: 10.1089/gtmb.2013.0424. Epub 2014 Feb 10.

PMID:
24512523
6.

Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.

Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M.

Int J Cancer. 2012 Apr 1;130(7):1590-7. doi: 10.1002/ijc.26111. Epub 2011 Nov 30.

7.

High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.

Konoplev SN, Fritsche HA, O'Brien S, Wierda WG, Keating MJ, Gornet TG, St Romain S, Wang X, Inamdar K, Johnson MR, Medeiros LJ, Bueso-Ramos CE.

Am J Clin Pathol. 2010 Sep;134(3):472-7. doi: 10.1309/AJCPHMYT93HUIZKW.

PMID:
20716805
8.

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.

Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry.

Clin Chem. 2010 Jun;56(6):e1-48. doi: 10.1373/clinchem.2009.133124. Epub 2010 Mar 5.

9.

Technical validation of an autoantibody test for lung cancer.

Murray A, Chapman CJ, Healey G, Peek LJ, Parsons G, Baldwin D, Barnes A, Sewell HF, Fritsche HA, Robertson JF.

Ann Oncol. 2010 Aug;21(8):1687-93. doi: 10.1093/annonc/mdp606. Epub 2010 Feb 2.

10.

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.

J Clin Oncol. 2009 Jul 10;27(20):3303-11. doi: 10.1200/JCO.2008.19.4423. Epub 2009 May 18.

PMID:
19451443
11.

Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer.

Grote T, Siwak DR, Fritsche HA, Joy C, Mills GB, Simeone D, Whitcomb DC, Logsdon CD.

Proteomics. 2008 Aug;8(15):3051-60. doi: 10.1002/pmic.200700951.

12.

Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.

Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ.

J Urol. 2008 Jun;179(6):2187-91; discussion 2191. doi: 10.1016/j.juro.2008.01.102. Epub 2008 Apr 18.

PMID:
18423725
13.

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ.

J Urol. 2008 May;179(5):1804-9; discussion 1809-10. doi: 10.1016/j.juro.2008.01.013. Epub 2008 Mar 18.

PMID:
18353398
14.

A multicenter evaluation of the Iris iQ200 automated urine microscopy analyzer body fluids module and comparison with hemacytometer cell counts.

Butch AW, Wises PK, Wah DT, Gornet TG, Fritsche HA.

Am J Clin Pathol. 2008 Mar;129(3):445-50. doi: 10.1309/WR1C5WNT6UFXNC6J.

PMID:
18285268
15.

Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70 degrees C or less.

Scaramuzzino DA, Schulte K, Mack BN, Soriano TF, Fritsche HA.

Int J Biol Markers. 2007 Jul-Sep;22(3):206-13.

PMID:
17922465
16.

Is there a role for serum human tissue kallikrein in detection of prostate cancer?

Ochiai A, Shukla A, Davis JW, Fritsche HA, Bhadkamkar V, Babaian RJ.

Urology. 2007 Sep;70(3):519-22.

PMID:
17905108
17.

Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.

Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V.

Clin Breast Cancer. 2007 Feb;7(6):471-9.

PMID:
17386124
18.

Fenretinide activity in retinoid-resistant oral leukoplakia.

Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA Jr, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R.

Clin Cancer Res. 2006 May 15;12(10):3109-14.

19.

The detection and potential economic value of complexed prostate specific antigen as a first line test.

Babaian RJ, Naya Y, Cheli C, Fritsche HA.

J Urol. 2006 Mar;175(3 Pt 1):897-901; discussion 901.

PMID:
16469574
20.

Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.

Erkanli A, Taylor DD, Dean D, Eksir F, Egger D, Geyer J, Nelson BH, Stone B, Fritsche HA, Roden RB.

Cancer Res. 2006 Feb 1;66(3):1792-8.

22.

Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.

Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.

Urol Oncol. 2005 Jan-Feb;23(1):16-21.

PMID:
15885578
23.

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW.

J Clin Oncol. 2005 Mar 1;23(7):1420-30. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808.

PMID:
15735118
24.
25.

Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.

Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.

Urology. 2004 Mar;63(3):492-8.

PMID:
15028444
26.

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS.

Lung Cancer. 2004 Apr;44(1):99-110.

PMID:
15013588
27.

Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.

Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN.

Cytokine. 2004 Feb 7;25(3):94-102.

PMID:
14698135
28.

Potential role for intraoperative gamma probe identification of normal parathyroid glands.

Pederson LC, Shapiro SE, Fritsche HA Jr, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE.

Am J Surg. 2003 Dec;186(6):711-7.

PMID:
14672784
29.

Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.

Naya Y, Fritsche HA, Cheli CD, Stamey TA, Bartsch G, Brawer MK, Childs S, Taneja SS, Lepor H, Partin AW, Sokoll LJ, Chan DW, Babaian RJ.

Urology. 2003 Dec;62(6):1058-62.

PMID:
14665355
30.

Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.

Sweep FC, Fritsche HA, Gion M, Klee GG, Schmitt M; EORTC-NCI Working Group.

Int J Oncol. 2003 Dec;23(6):1715-26.

PMID:
14612946
31.

Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.

Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP, Cheli CD.

J Urol. 2003 Nov;170(5):1787-91.

PMID:
14532777
32.

Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization.

Coombes KR, Fritsche HA Jr, Clarke C, Chen JN, Baggerly KA, Morris JS, Xiao LC, Hung MC, Kuerer HM.

Clin Chem. 2003 Oct;49(10):1615-23.

33.

Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients.

Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jäger W, van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M, Domke I.

Clin Lab. 2003;49(1-2):15-24.

PMID:
12593471
34.

High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.

Kuerer HM, Thompson PA, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, Singletary SE, Cristofanilli M, Sneige N, Hunt KK.

Clin Cancer Res. 2003 Feb;9(2):601-5.

35.

Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression.

Royal RE, Delpassand ES, Shapiro SE, Fritsche HA Jr, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE.

Surgery. 2002 Dec;132(6):968-74; discussion 974-5.

PMID:
12490843
36.

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.

Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK.

J Clin Oncol. 2002 Nov 15;20(22):4440-7.

PMID:
12431966
37.

Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?

Naya Y, Stamey TA, Cheli CD, Partin AW, Sokoll LJ, Chan DW, Brawer MK, Taneja SS, Lepor H, Bartsch G, Childs S, Fritsche HA, Babaian RJ.

Urology. 2002 Oct;60(4 Suppl 1):36-41.

PMID:
12384161
38.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G.

Urology. 2002 Oct;60(4 Suppl 1):31-5.

PMID:
12384160
39.

Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.

Taneja SS, Hsu EI, Cheli CD, Walden P, Bartsch G, Horninger W, Babaian RJ, Fritsche HA, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Lepor H.

Urology. 2002 Oct;60(4 Suppl 1):10-7.

PMID:
12384157
40.

Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.

Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM.

Clin Cancer Res. 2002 Sep;8(9):2835-42.

41.

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN.

J Clin Oncol. 2002 Apr 1;20(7):1800-8.

PMID:
11919237
42.

Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay.

Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jäger W, van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M, Domke I.

Clin Chem. 2001 Dec;47(12):2162-4. No abstract available.

43.
44.

The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.

Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA HA Jr.

J Urol. 2001 Mar;165(3):757-60.

PMID:
11176461
45.

Lactate dehydrogenase isoenzyme 1 is the most important LD isoenzyme in patients with testicular germ cell tumor.

von Eyben FE, Liu FJ, Amato RJ, Fritsche HA.

Acta Oncol. 2000;39(4):509-17.

PMID:
11041114
46.

N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.

Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R, Hong WK.

Clin Cancer Res. 2000 Aug;6(8):2973-9.

47.

Calcium-induced activation of a mutant G-protein-coupled receptor causes in vitro transformation of NIH/3T3 cells.

Hoff AO, Cote GJ, Fritsche HA Jr, Qiu H, Schultz PN, Gagel RF.

Neoplasia. 1999 Dec;1(6):485-91.

48.

Relative contributions of technetium Tc 99m sestamibi scintigraphy, intraoperative gamma probe detection, and the rapid parathyroid hormone assay to the surgical management of hyperparathyroidism.

Dackiw AP, Sussman JJ, Fritsche HA Jr, Delpassand ES, Stanford P, Hoff A, Gagel RF, Evans DB, Lee JE.

Arch Surg. 2000 May;135(5):550-5; discussion 555-7. Review.

PMID:
10807279
49.

Does the fountain epitope model's rhythmic hydropathy continuum pattern satisfy the requirements of a nucleic acid meta-code or protein meta-form?

Kokolus WJ, Johnston DA, Fritsche HA.

Ann N Y Acad Sci. 1999 May 18;870:423-7. No abstract available.

PMID:
10415513
50.

Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder.

Hughes JH, Katz RL, Rodriguez-Villanueva J, Kidd L, Dinney C, Grossman HB, Fritsche HA Jr.

Diagn Cytopathol. 1999 May;20(5):285-90.

PMID:
10319229

Supplemental Content

Loading ...
Support Center